Capricor Therapeutics (NASDAQ: CAPR) — Perfil da empresa, notícias e dados financeiros
Capricor Therapeutics focuses on developing cell and exosome-based therapeutics for cardiovascular and muscular diseases.
Capricor Therapeutics
Capricor Therapeutics (NASDAQ:CAPR) specializes in biotechnology with a strong focus on developing transformative cell and exosome-based therapeutics for treating a variety of disorders, particularly those related to cardiovascular and muscular diseases. The company is dedicated to leveraging its innovative technology to address significant unmet medical needs, with a pipeline that includes candidates aimed at conditions such as Duchenne muscular dystrophy and complications related to COVID-19. Capricor's objective is to improve patient outcomes through pioneering research and the advancement of its therapeutic platforms, demonstrating a commitment to excellence and innovation in the field of biomedicine.
Resumo
Operações
Produtos e/ou serviços de Capricor Therapeutics
- CAP-1002, a cell therapy product for Duchenne muscular dystrophy and other conditions.
- Exosome platform for developing treatments for various diseases.
- CAP-2003 (derived from CAP-1002), being investigated for ocular disorders and regenerative medicine.
- Research partnerships and collaborations to advance cell and exosome therapy applications.
- Product pipeline for addressing unmet medical needs in rare diseases.
- Technology licensing agreements to leverage proprietary technologies for broader therapeutic uses.
equipe executiva do Capricor Therapeutics
- Frank Isaac LitvackExecutive Chairman of the Board
- Linda MarbánCo-Founder, President, CEO & Director
- Anthony J. BergmannCFO & Corporate Treasurer
- Karen G. KrasneyExecutive VP, General Counsel & Secretary
- Kristi A. H. ElliottChief Operating & Science Officer
- Minghao SunSenior Vice President of Quality Control, Research & Product Development
- Mark AwadallaChief Development Officer
- Micheal BinksChief Medical Officer
- Michael MaurerChief Commercial Officer
- Nathaniel HoganDirector of Biostatistics of Capricor Therapeutics
Principais indicadores financeiros
Resultados divulgados pela Capricor Therapeutics, em USD.
- Cap. de mercado
- 362,2 mi
- Receita (TTM)
- 11,1 mi
- P/L
- —
- LPA (diluído, TTM)
- -2.5
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -108,1 mi | -105 mi | |
| 22,3 mi | -42,6 mi | -40,5 mi | |
| 25,2 mi | -24,1 mi | -22,3 mi | |
| 2,6 mi | -29,7 mi | -29 mi |